Vertex Pharmaceuticals Q4 EPS $4.20 Beats $4.10 Estimate, Sales $2.52B Beat $2.51B Estimate
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals (NASDAQ:VRTX) exceeded Q4 earnings and sales estimates with an EPS of $4.20, surpassing the $4.10 forecast, and reported sales of $2.52B, slightly above the $2.51B estimate. This represents an 11.7% increase in EPS and a 9.32% increase in sales compared to the same period last year.
February 05, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals reported a strong Q4 with EPS and sales exceeding estimates, showcasing significant year-over-year growth.
Beating both earnings and sales estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. The reported year-over-year growth in both EPS and sales further strengthens the case for a positive outlook on VRTX's stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100